In AD mouse models, overexpression of SIRT1 or treatment with SIRT1 activators results in lower Aβ production and plaque burden, as well as enhanced clearance of Aβ peptides (Campagna et al., 2018; Islam et al., 2022). The gene discussed is SIRT1; the disease is Alzheimer disease.